Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1DU20)

• Drug Name: GSK3882347 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM1DU20

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Fimbrin D-mannose adhesin (Bact FimH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EB8018	DM753H8	Crohn disease	DD70	Phase 2	[3]
Biaryl mannoside derivative 24	DMF5TB4	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-5	DMH7XL3	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-116	DMJ3201	Crohn disease	DD70	Patented	[4]
Biaryl mannoside derivative 8	DMWF2VG	Crohn disease	DD70	Patented	[4]
Beta-cyclodextrin conjugate derivative 3	DMQJF4P	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-109	DM01IWV	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-114	DM5GHJA	Crohn disease	DD70	Patented	[4]
Biphenyl mannoside derivative 6	DM93VEB	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-5d	DMF6Z5I	Crohn disease	DD70	Patented	[4]
EB8018	DM753H8	Crohn disease	DD70	Phase 2	[3]
Biaryl mannoside derivative 24	DMF5TB4	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-5	DMH7XL3	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-116	DMJ3201	Crohn disease	DD70	Patented	[4]
Biaryl mannoside derivative 8	DMWF2VG	Crohn disease	DD70	Patented	[4]
Beta-cyclodextrin conjugate derivative 3	DMQJF4P	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-109	DM01IWV	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-114	DM5GHJA	Crohn disease	DD70	Patented	[4]
Biphenyl mannoside derivative 6	DM93VEB	Crohn disease	DD70	Patented	[4]
PMID26651364-Compound-5d	DMF6Z5I	Crohn disease	DD70	Patented	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Fimbrin D-mannose adhesin (Bact FimH)	TTTCRU2	FIMH_ECOLI	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT05138822) A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Fimbrion Therapeutics
• [3] Clinical pipeline report, company report or official report of Enterome Biosciences.
• [4] Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.